M&A Deal Summary

Todos Medical Acquires Provista Diagnostics

On January 9, 2020, Todos Medical acquired life science company Provista Diagnostics

Acquisition Highlights
  • This is Todos Medical’s 1st transaction in the Life Science sector.
  • This is Todos Medical’s 1st transaction in the United States.
  • This is Todos Medical’s 1st transaction in Georgia.

M&A Deal Summary
Date 2020-01-09
Target Provista Diagnostics
Sector Life Science
Buyer(s) Todos Medical
Deal Type Add-on Acquisition

Target

Provista Diagnostics

Alpharetta, Georgia, United States
Provista Diagnostics, Inc. is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, the high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA).

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Todos Medical

Rehovot, Israel
Category Company
Founded 2010
Sector Life Science
DESCRIPTION

Todos Medical Ltd. is an in-vitro diagnostics company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Georgia) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Mergr

Product

Company

Legal